Ossur hf: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
Provider: Wright Reports
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Ossur hf Reiterates FY 2013 Financial Guidance
Ossur hf announced that the Company's Management reiterates its previous guidance for the fiscal year 2013. LCY organic sales growth was initially expected to be in the range of 2-4% and adjusted EBITDA margin 18-19%. As communicated in the Q1 2013 report, Management expects the results for the fiscal year 2013 to be in the lower end of the guided range, both in terms of sales and EBITDA.
Latest Key Developments in Medical
- YOOX SpA enters FTSE MIB of Borsa Italiana on Dec. 23 and DiaSorin SpA and Parmalat exit-Reuters
- Landauer Inc gives FY 2014 guidance; earnings guidance below analysts' estimates
- Baxter International Inc files for pediatric indication of RIXUBIS
- Covidien PLC announces definitive agreement to acquire Given Imaging Ltd
- Share this
- Digg this